Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses
Host genetic and environmental factors including age, biological sex, diet, geographical
location, microbiome composition and metabolites converge to influence innate and …
location, microbiome composition and metabolites converge to influence innate and …
The second decade of anti-TNF-a therapy in clinical practice: New lessons and future directions in the COVID-19 era
Since the late 1990s, tumor necrosis factor alpha (TNF-α) inhibitors (anti-TNFs) have
revolutionized the therapy of immune-mediated inflammatory diseases (IMIDs) affecting the …
revolutionized the therapy of immune-mediated inflammatory diseases (IMIDs) affecting the …
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort …
Background In rituximab-treated patients with rheumatoid arthritis, humoral and cellular
immune responses after two or three doses of SARS-CoV-2 vaccines are not well …
immune responses after two or three doses of SARS-CoV-2 vaccines are not well …
The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future
A Antinori, M Bausch-Jurken - The Journal of Infectious …, 2023 - academic.oup.com
Approximately 3% of US adults are immunocompromised and less capable of fighting
infections such as SARS-CoV-2 (the causative agent of COVID-19). Individuals may be …
infections such as SARS-CoV-2 (the causative agent of COVID-19). Individuals may be …
Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
Background The causes for immune-mediated inflammatory diseases (IMIDs) are diverse
and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to …
and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to …
Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα
H Edelman-Klapper, E Zittan, ABG Shitrit… - Gastroenterology, 2022 - Elsevier
Background & Aim Patients with inflammatory bowel diseases (IBD), specifically those
treated with anti–tumor necrosis factor (TNF) α biologics, are at high risk for vaccine …
treated with anti–tumor necrosis factor (TNF) α biologics, are at high risk for vaccine …
Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
SW Syversen, I Jyssum, AT Tveter… - Arthritis & …, 2022 - Wiley Online Library
Objective Immunogenicity and safety following receipt of the standard SARS–CoV‐2
vaccination regimen in patients with immune‐mediated inflammatory diseases (IMIDs) are …
vaccination regimen in patients with immune‐mediated inflammatory diseases (IMIDs) are …
Kinetics of the B-and T-cell immune responses after 6 months from SARS-CoV-2 mRNA vaccination in patients with rheumatoid arthritis
Objective To assess the kinetics of the humoral and cell-mediated responses after severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in rheumatoid arthritis …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in rheumatoid arthritis …
Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis
Background And Aims The serological responses after severe acute respiratory syndrome
coronavirus 2 vaccination may be attenuated in immunocompromised individuals. The study …
coronavirus 2 vaccination may be attenuated in immunocompromised individuals. The study …
[HTML][HTML] Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases
RM Dayam, JC Law, RL Goetgebuer, GYC Chao… - JCI insight, 2022 - ncbi.nlm.nih.gov
BACKGROUND Limited information is available on the impact of immunosuppressants on
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …